FDA Adverse Event Malfunction Summary report: N

COBAS INFINITY CORE SOFTWARE

MDR report key: 8992478 · Received September 11, 2019

Report

Report Number
1823260-2019-03268
Event Type
Malfunction
Date Received
September 11, 2019
Date of Event
August 21, 2019
Report Date
October 8, 2019
Manufacturer
ROCHE DIAGNOSTICS
Product Code
JQP
PMA / PMN Number
EXEMPT
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
BE
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

THE INVESTIGATION REPRODUCED AND CONFIRMED THE ISSUE IN THE REPORTED SOFTWARE VERSION (3.00.00) AND IN THE LATEST AVAILABLE VERSION OF THE SOFTWARE (3.01.02). THE AFFECTED SOFTWARE VERSIONS 3.00.00 OR HIGHER WERE NOT LAUNCHED IN THE UNITED STATES. BASED ON THIS INFORMATION, THIS EVENT COULD NOT OCCUR IN THE UNITED STATES, THEREFORE, THERE IS NO RISK TO USERS IN THE UNITED STATES.

Additional Manufacturer Narrative · 1

THE INVESTIGATION HAS BEEN ABLE TO REPRODUCE THE CUSTOMER'S ALLEGATION. THE INVESTIGATION IS CURRENTLY ONGOING. THE EVENT OCCURRED IN: (B)(6).

Description of Event or Problem · 1

THE INITIAL REPORTER STATED THAT THERE IS A PROBLEM WITH THE COBAS INFINITY SOFTWARE (VERSION 3.00.00) THAT COULD AFFECT THE INTERPRETATION OF PATIENT RESULTS. WHEN CHANGING A TEST RULE FOR ONE APPLICATION IN THE COBAS INFINITY SOFTWARE, THE RULES FOR OTHER TESTS WERE BEING INAPPROPRIATELY CHANGED. FOR EXAMPLE, THE CUSTOMER CHANGED THE INSTRUMENTS THAT WERE ASSIGNED TO THE RULE "RERUN W DEC." WITHIN 1 SECOND THE RULES FOR THE FT3 TESTS WERE CHANGED FROM "65-FT3-VRIJE T3" TO "152-LH-2-LH STAAL 2." THE FT3 RULES SHOULD NOT HAVE BEEN CHANGED. THIS COULD AFFECT HOW PATIENT RESULTS ARE HANDLED BY THE INFINITY SOFTWARE AND HOW THEY ARE INTERPRETED BY THE USER. THERE HAVE BEEN NO ALLEGATIONS OF ANY PATIENT RESULTS BEING AFFECTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
792946 COBAS INFINITY CORE SOFTWARE CALCULATOR/DATA PROCESSING MODULE, FOR CLINICAL USE JQP ROCHE DIAGNOSTICS NA NA

Patients

Seq Age Sex Outcome Treatment
1